Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 1
1966 1
1967 2
1968 3
1969 3
1971 3
1975 1
1976 4
1978 3
1979 3
1980 1
1981 9
1982 3
1983 7
1984 3
1985 2
1986 3
1987 9
1988 7
1989 4
1990 9
1991 15
1992 14
1993 10
1994 12
1995 13
1996 16
1997 15
1998 14
1999 12
2000 20
2001 19
2002 24
2003 29
2004 44
2005 36
2006 28
2007 34
2008 39
2009 49
2010 50
2011 52
2012 50
2013 54
2014 58
2015 72
2016 48
2017 70
2018 62
2019 42
2020 48
2021 55
2022 45
2023 49
2024 45
2025 45

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,243 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Among authors: masuda n. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Robson M, et al. Among authors: masuda n. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. N Engl J Med. 2017. PMID: 28578601 Free article. Clinical Trial.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. Cristofanilli M, et al. Among authors: masuda n. Clin Cancer Res. 2022 Aug 15;28(16):3433-3442. doi: 10.1158/1078-0432.CCR-22-0305. Clin Cancer Res. 2022. PMID: 35552673 Free PMC article. Clinical Trial.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Turner NC, et al. Among authors: masuda n. N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345905 Clinical Trial.
Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.
Im SA, Mukai H, Park IH, Masuda N, Shimizu C, Kim SB, Im YH, Ohtani S, Huang Bartlett C, Lu DR, Iyer S, Mori Y, Mori A, Gauthier E, Finn RS, Toi M. Im SA, et al. Among authors: masuda n. J Glob Oncol. 2019 May;5:1-19. doi: 10.1200/JGO.18.00173. J Glob Oncol. 2019. PMID: 31125276 Free PMC article. Clinical Trial.
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Holmes FA, Moy B, Delaloge S, Chia SKL, Ejlertsen B, Mansi J, Iwata H, Gnant M, Buyse M, Barrios CH, Silovski T, Šeparović R, Bashford A, Zotano AG, Denduluri N, Patt D, Gokmen E, Gore I, Smith JW 2nd, Loibl S, Masuda N, Tomašević Z, Petráková K, DiPrimeo D, Wong A, Martin M, Chan A; ExteNET Study Group. Holmes FA, et al. Among authors: masuda n. Eur J Cancer. 2023 May;184:48-59. doi: 10.1016/j.ejca.2023.02.002. Epub 2023 Feb 10. Eur J Cancer. 2023. PMID: 36898233 Free article. Clinical Trial.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Takada M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Ohno S, Ishiguro H, Kanbayashi C, Miyamoto T, Hagiwara Y, Toi M. Takada M, et al. Among authors: masuda n. Breast Cancer Res Treat. 2023 Dec;202(3):485-496. doi: 10.1007/s10549-023-07099-4. Epub 2023 Sep 7. Breast Cancer Res Treat. 2023. PMID: 37676450 Free PMC article.
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS, Huober J, García-Sáenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. Rugo HS, et al. Among authors: masuda n. Oncologist. 2021 Jan;26(1):e53-e65. doi: 10.1002/onco.13531. Epub 2020 Oct 9. Oncologist. 2021. PMID: 32955138 Free PMC article.
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.
Yamamoto Y, Iwata H, Saji S, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Taira N, Morita S, Toi M, Ohno S, Masuda N. Yamamoto Y, et al. Among authors: masuda n. J Clin Oncol. 2025 May 10;43(14):1631-1637. doi: 10.1200/JCO-24-01673. Epub 2025 Jan 24. J Clin Oncol. 2025. PMID: 39854662 Free PMC article. Clinical Trial.
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N. Yamashita T, et al. Among authors: masuda n. J Clin Oncol. 2025 Apr 10;43(11):1302-1313. doi: 10.1200/JCO-24-01888. Epub 2025 Jan 9. J Clin Oncol. 2025. PMID: 39787453 Free PMC article. Clinical Trial.
1,243 results